基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02616 基石药业-B

未开盘 07-14 16:08:21

5.200

-0.160

-2.99%

最高5.310	最低4.940	成交量1,906万
今开5.310	昨收5.360	日振幅6.90%
总市值70.98亿	流通市值70.98亿	总股本13.65亿
成交额9,709万	换手率1.40%	流通股本13.65亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02616","market":"HK","secType":"STK","nameCN":"基石药业-B","latestPrice":5.2,"timestamp":1752480501078,"preClose":5.36,"halted":0,"volume":19057000,"delay":0,"floatShares":1365000000,"shares":1365000000,"eps":-0.07821589128745358,"marketStatus":"未开盘","change":-0.16,"latestTime":"07-14 16:08:21","open":5.31,"high":5.31,"low":4.94,"amount":97091127,"amplitude":0.06903,"askPrice":5.21,"askSize":35000,"bidPrice":5.2,"bidSize":91500,"shortable":0,"etf":0,"ttmEps":-0.07821589128745358,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752543000000},"marketStatusCode":0,"adr":0,"listingDate":1551110400000,"exchange":"SEHK","adjPreClose":5.36,"openAndCloseTimeList":[[1752456600000,1752465600000],[1752469200000,1752480000000]],"volumeRatio":0.7643444699512579,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02616","defaultTab":"news","newsList":[{"id":"2551689922","title":"基石药业-B盘中异动 早盘大幅跳水5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551689922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551689922?lang=zh_cn&edition=full","pubTime":"2025-07-14 09:36","pubTimestamp":1752456983,"startTime":"0","endTime":"0","summary":"2025年07月14日早盘09时36分，基石药业-B股票出现异动，股价急速跳水5.04%。截至发稿，该股报5.090港元/股，成交量226.6万股，换手率0.17%，振幅4.66%。基石药业-B股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，北海康成-B、中国抗体-B、博安生物涨幅较大，振幅较大的相关个股有北海康成-B、乐普生物-B、创胜集团-B，振幅分别为24.32%、5.71%、4.88%。配售股份占现有已发行股本约7.3%，完成后占扩大股本约6.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714093624a448a2e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714093624a448a2e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2550936565","title":"基石药业-B07月11日主力净流入23.5万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550936565","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550936565?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:15","pubTimestamp":1752221740,"startTime":"0","endTime":"0","summary":"07月11日, 基石药业-B股价涨0.37%，报收5.36元，成交金额8280.9万元，换手率1.12%，振幅8.61%，量比0.60。基石药业-B今日主力资金净流入23.5万元，上一交易日主力净流出370.1万元。该股近5个交易日上涨3.28%，主力资金累计净流出2396.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出3392.4万元，其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711170214a444700d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711170214a444700d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2550981261","title":"基石药业（2616）公告：通过一般授权配售新股募资约4.7亿港元 抗肿瘤药物研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2550981261","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550981261?lang=zh_cn&edition=full","pubTime":"2025-07-11 15:20","pubTimestamp":1752218451,"startTime":"0","endTime":"0","summary":"来源：新浪港股-好仓工作室2025年7月9日，基石药业公告称，通过一般授权以“配售新股”方式融资，配售100,000,000股，募集约4.7亿港元。配售新股配售价4.72港元，较前一交易日收市价5.18港元折让约8.9%，较前五个交易日平均收市价折让约3.0%。配售股份占现有已发行股本约7.3%，完成后占扩大股本约6.8%。基石药业是一家专注于抗肿瘤药物研发的创新型生物制药公司。本次发行根据股东大会授予的一般授权实施，预计于2025年7月16日完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711152428a6a32dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711152428a6a32dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2550643108","title":"PD-L1单抗再出海，基石药业火力全开！","url":"https://stock-news.laohu8.com/highlight/detail?id=2550643108","media":"CPHI制药在线","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550643108?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:30","pubTimestamp":1752136258,"startTime":"0","endTime":"0","summary":"关注并星标CPHI制药在线最近几天，基石药业的好消息接二连三。在经过几年的裁员、关厂、卖管线后，基石药业再度火力全开。核心单品，开疆拓土舒格利单抗是一款全人源全长抗PD-L1单克隆抗体，其开发是基石药业基于美国Ligand公司授权引进的OmniRat转基因动物平台。基石药业成为首家将国产PD-L1单抗推向国际市场的创新生物医药企业。此次交易使得基石药业当天早盘股价上涨14.89%，股价创2023年2月以来新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164726a6a13374&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710164726a6a13374&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2550269637","title":"高盛：中国生物医药产品出海授权趋势属结构性转变，而非短暂反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2550269637","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550269637?lang=zh_cn&edition=full","pubTime":"2025-07-10 10:38","pubTimestamp":1752115099,"startTime":"0","endTime":"0","summary":"高盛发表中国医药产行业报告，中国生物科技企业的产品出海授权趋势推动上半年股价表现强劲，近期市场对交易持续性及估值可持续性的讨论开始浮现。该行认为经过对授权交易及中国创新药管线在全球背景下的深入分析，该行认为这是一场结构性转变，而非短暂反弹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710104247953ce4c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710104247953ce4c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","BK1161","01801","LU1969619763.USD","LU2328871848.SGD","LU2488822045.USD","02616","BK1583"],"gpt_icon":1},{"id":"1184330275","title":"生物医药盘初走高，基石药业涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184330275","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184330275?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:33","pubTimestamp":1752111196,"startTime":"0","endTime":"0","summary":"7月10日（周四），生物医药盘初走高，基石药业涨近5%，再鼎医药、康方生物、百济神州、康诺亚涨超2%","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"74b6009d1f0b864a45511e283c96b8f2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","02616","02162"],"gpt_icon":0},{"id":"2550610866","title":"基石药业-B(02616)：普吉华®(普拉替尼胶囊)由境外转移至境内生产的药品上市注册申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2550610866","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550610866?lang=zh_cn&edition=full","pubTime":"2025-07-10 08:04","pubTimestamp":1752105872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，其RET抑制剂普吉华由境外转移至境内生产的药品上市申请已获中国国家药品监督管理局批准。预计于2026年起，该产品在中国大陆市场的供应将由进口产品逐渐过渡为国内地产化产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)：普吉华®(普拉替尼胶囊)由境外转移至境内生产的药品上市注册申请获国家药监局批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","02616"],"gpt_icon":0},{"id":"2550668878","title":"高盛：上调基石药业-B(02616)评级至“买入” 目标价6.25港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550668878","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550668878?lang=zh_cn&edition=full","pubTime":"2025-07-09 14:53","pubTimestamp":1752043981,"startTime":"0","endTime":"0","summary":"该行鉴于管线2.0出海能见度提升，将永续增长率从1%上调至2%。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20250709/20250709145418_91526.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250709/20250709145418_91526.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02616"],"gpt_icon":0},{"id":"2550562505","title":"PD-1/VEGF三抗崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2550562505","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550562505?lang=zh_cn&edition=full","pubTime":"2025-07-09 10:26","pubTimestamp":1752027983,"startTime":"0","endTime":"0","summary":"近日，基石药业宣布，其自主研发的潜在同类首创/同类最佳的CS2009最新临床进展。该药具有均衡的单价PD-1和CTLA-4结合臂以及双价VEGFA结合臂，可产生强效多靶点协同效应以及优先靶向肿瘤组织以降低系统性毒性。除了基石药业的CS2009，上海宏成药业也开发了一款PD-1/CTLA-4/VEGF的三特异性抗体HC010，目前正在进行一项评估HC010治疗晚期实体瘤患者的安全性、药代动力学和抗肿瘤活性的多中心、开放、剂量递增和剂量扩展I期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709102835a69e4925&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2550574814","title":"基石药业-B拟折让8.88%配售合共1亿股配售股份 总筹4.72亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550574814","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550574814?lang=zh_cn&edition=full","pubTime":"2025-07-09 08:11","pubTimestamp":1752019860,"startTime":"0","endTime":"0","summary":"格隆汇7月9日丨基石药业-B发布公告，2025年7月8日，公司与配售代理订立配售协议，据此，公司已有条件同意透过配售代理，以每股配售股份4.72港元的价格，向不少于六名承配人配售合共1亿股配售股份。配售股份将根据一般授权配发及发行，且无需取得任何股东批准。假设所有配售股份悉数获配售，则配售估计所得款项总额及净额将分别为约4.72亿港元及约4.67亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709081309a43ee89d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709081309a43ee89d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0},{"id":"2550797905","title":"13.8亿！国产PD-L1抗体再出海，基石药业“舒格利单抗”打通西欧市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2550797905","media":"药渡","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550797905?lang=zh_cn&edition=full","pubTime":"2025-07-09 07:31","pubTimestamp":1752017514,"startTime":"0","endTime":"0","summary":"基石药业通过向Gentili供货，还将持续获得授权区域内舒格利单抗近50%净销售额的营业收入。舒格利单抗的研发基于多项临床试验的成功。此次西欧合作标志着基石药业已完成对欧洲主要市场的全面覆盖。通过与Gentili的合作，基石药业将加速舒格利单抗在欧洲的注册及商业化相关活动，为更多患者提供创新治疗方案。金赛药业痛风新药“伏欣奇拜单抗”获批上市","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709074005a69df494&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709074005a69df494&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1574","BK1161"],"gpt_icon":0},{"id":"2549519638","title":"海外授权交易成医药行业发展重要引擎！该药企业今日高开近15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549519638","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549519638?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:04","pubTimestamp":1751961893,"startTime":"0","endTime":"0","summary":"基于这一消息，基石药业今日早盘高开近15%，报5.94港元，股价创2023年2月以来新高。从行业角度来看，此类海外授权交易对医药行业的提振作用是多维度的。海外授权交易作为连接国内外医药资源的桥梁，正持续为医药行业带来新的发展机遇与活力，助力行业在创新研发、市场拓展等多方面迈向新的高度，推动全球医药健康事业不断向前发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708160607953a91cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708160607953a91cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2549567878","title":"基石药业-B盘中异动 早盘急速上涨9.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567878","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567878?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:41","pubTimestamp":1751938880,"startTime":"0","endTime":"0","summary":"2025年07月08日早盘09时41分，基石药业-B股票出现异动，股价大幅拉升9.67%。截至发稿，该股报5.670港元/股，成交量1269.63万股，换手率0.93%，振幅18.57%。基石药业-B股票所在的生物技术行业中，整体涨幅为0.10%。其相关个股中，基石药业-B、正大企业国际、圣诺医药-B涨幅较大，振幅较大的相关个股有基石药业-B、北海康成-B、创胜集团-B，振幅分别为18.57%、12.79%、9.09%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708094120a43cd91f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708094120a43cd91f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"1141327845","title":"生物医药B类股走强，基石药业-B涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141327845","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141327845?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:34","pubTimestamp":1751938452,"startTime":"0","endTime":"0","summary":"周二生物医药B类股走强，生物医药B类股走强，$基石药业-B$涨超10%，与欧洲Gentili达成独家战略合作，$荣昌生物$涨近6%，$加科思$涨近4%，$北海康成-B$涨超3%，$云顶新耀$、$和铂医药-B$、$复宏汉霖$涨超2%，$亚盛医药$、歌礼制药、$心玮医疗-B$涨超1%。基石药业-B发布公告，基石药业与一家专注肿瘤领域，并在欧洲市场深耕百年的生物医药公司 Istituto Gentili就舒格利单抗在西欧和英国的商业化达成独家战略合作。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0e5a574d4b7f81768342a3b0afe52242","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","02616","09995","01228","01952","01167"],"gpt_icon":0},{"id":"1126882033","title":"异动解读 | 基石药业-B股价盘中大涨5.42%，与欧洲药企达成重要合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1126882033","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126882033?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:32","pubTimestamp":1751938346,"startTime":"0","endTime":"0","summary":"基石药业-B今日盘中大涨5.42%，引发市场关注。截至发稿，该股报5.94港元，创下近17个月新高。消息面上，基石药业今日宣布与欧洲知名生物医药公司Istituto Gentili就其重磅产品舒格利单抗在西欧和英国的商业化达成独家战略合作。分析人士认为，这项合作有望加速舒格利单抗在欧洲市场的商业化进程，显著扩大产品的国际市场覆盖。舒格利单抗是首个在欧盟及英国获批用于联合化疗一线治疗IV期非小细胞肺癌全人群的PD-L1单抗，具有重要的临床价值。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0e5a574d4b7f81768342a3b0afe52242","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02616"],"gpt_icon":0},{"id":"2549569529","title":"基石药业-B(02616)与Istituto Gentili就舒格利单抗在西欧和英国达成独家战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2549569529","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549569529?lang=zh_cn&edition=full","pubTime":"2025-07-08 08:06","pubTimestamp":1751933172,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 发布公告，基石药业与一家专注肿瘤领域，并在欧洲市场深耕百年的生物医药公司 Istituto Gentili就舒格利单抗在西欧和英国的商业化达成独家战略合作。基石药业将从Gentili获得首付款、注册及销售里程碑付款，交易总金额最高可达1.925亿美元。此外，通过向Gentili供应舒格利单抗，本公司还将获得授权区域内舒格利单抗近50%净销售额的营收分成。Gentili将负责舒格利单抗在上述地区的注册及商业化相关活动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0e5a574d4b7f81768342a3b0afe52242","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314926.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"基石药业-B(02616)与Istituto Gentili就舒格利单抗在西欧和英国达成独家战略合作","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02616","BK1574"],"gpt_icon":0},{"id":"2549303377","title":"基石药业-B盘中异动 早盘快速拉升5.39%报5.470港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549303377","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549303377?lang=zh_cn&edition=full","pubTime":"2025-07-07 09:30","pubTimestamp":1751851806,"startTime":"0","endTime":"0","summary":"2025年07月07日早盘09时30分，基石药业-B股票出现异动，股价快速拉升5.39%。截至发稿，该股报5.470港元/股，成交量57.05万股，换手率0.04%，振幅1.73%。资金方面，该股资金流入44.548万港元，流出129.794万港元。其相关个股中，基石药业-B、博安生物、泰格医药涨幅较大，振幅较大的相关个股有科伦博泰生物-B、泰格医药、北海康成-B，振幅分别为2.98%、1.50%、1.45%。基石药业-B公司简介：基石药业是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707093006a699d5f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707093006a699d5f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2549726493","title":"基石药业-B(02616)：目前CS2009在所有已评估的剂量水平上展现出良好的耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=2549726493","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549726493?lang=zh_cn&edition=full","pubTime":"2025-07-07 08:22","pubTimestamp":1751847746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，基石药业-B 公布CS2009最新临床进展。截至目前，CS2009在所有已评估的剂量水平上展现出良好的耐受性，优异的药代动力学特征支持每三周给药一次的治疗方案，药效学数据亦证实CS2009触发的PD1/CTLA-4阻断启动T细胞及对VEGFA的中和作用，并且已在低剂量组的“冷肿瘤”及PD-1经治患者中观察到抗肿瘤活性。据悉，CS2009的I期研究为全球多中心临床试验，Ia期研究为剂量递增与补充入组，旨在晚期实体瘤患者中评价CS2009的安全性、耐受性、PK和抗肿瘤活性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2548394504","title":"基石药业-B(02616)公布Nofazinlimab治疗肝细胞癌的国际多中心 III期研究的最新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2548394504","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548394504?lang=zh_cn&edition=full","pubTime":"2025-07-04 22:34","pubTimestamp":1751639654,"startTime":"0","endTime":"0","summary":"据悉，Nofazinlimab是一种靶向人程序性细胞死亡蛋白1的人源化重组IgG4单克隆抗体，正在开发用于肿瘤的免疫治疗。Nofazinlimab与人类、食蟹猴和小鼠PD-1均具有高亲和力，可阻断 PD-1与PD-L1和PD-L2配体的相互作用。Nofazinlimab已于2020年7月获美国食品药品监督管理局授予孤儿药资格，用于治疗肝细胞癌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1314299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","02616","III","BK1161","BK1574"],"gpt_icon":0},{"id":"2548615483","title":"基石药业-B07月04日主力净流入1682.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548615483","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548615483?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:15","pubTimestamp":1751616905,"startTime":"0","endTime":"0","summary":"07月04日, 基石药业-B股价涨13.07%，报收5.19元，成交金额9397.0万元，换手率1.41%，振幅15.25%，量比2.14。基石药业-B今日主力资金净流入1682.4万元，上一交易日主力净流出10.6万元。该股近5个交易日上涨19.04%，主力资金累计净流入1238.6万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流出2457.8万元，其中净流出天数为15日。该股主力净额占比0.24%，港股市场排名28/2666。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704165244a72e7724&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704165244a72e7724&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","02616","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cstonepharma.com","stockEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.1354},{"period":"3month","weight":0.9623},{"period":"6month","weight":1.4645},{"period":"1year","weight":3.4068},{"period":"ytd","weight":1.2609}],"compareEarnings":[{"period":"1week","weight":0.0132},{"period":"1month","weight":0.013},{"period":"3month","weight":0.1275},{"period":"6month","weight":0.255},{"period":"1year","weight":0.3231},{"period":"ytd","weight":0.2065}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"基石药业是一家中国投资控股公司。该公司通过子公司主要从事生物制药产品的研发、生产和销售业务。该公司主要产品是肿瘤免疫治疗疗法和分子靶向药物。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.062298},{"month":2,"riseRate":0.333333,"avgChangeRate":0.039956},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.10478},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.048094},{"month":5,"riseRate":0.5,"avgChangeRate":0.100514},{"month":6,"riseRate":0.714286,"avgChangeRate":0.09443},{"month":7,"riseRate":0.571429,"avgChangeRate":-0.011191},{"month":8,"riseRate":0.333333,"avgChangeRate":0.010588},{"month":9,"riseRate":0.5,"avgChangeRate":-0.033892},{"month":10,"riseRate":0.5,"avgChangeRate":0.015157},{"month":11,"riseRate":0.666667,"avgChangeRate":0.016123},{"month":12,"riseRate":0.5,"avgChangeRate":0.028191}],"exchange":"SEHK","name":"基石药业-B","nameEN":"CSTONE PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"基石药业-B,02616,基石药业-B股票,基石药业-B股票老虎,基石药业-B股票老虎国际,基石药业-B行情,基石药业-B股票行情,基石药业-B股价,基石药业-B股市,基石药业-B股票价格,基石药业-B股票交易,基石药业-B股票购买,基石药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"基石药业-B(02616)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供基石药业-B(02616)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}